Alzheimer disease, attention, and the cholinergic system

Area of Science:

• Neuropsychology
• Neuropharmacology
• Cognitive Science

Background:

• Alzheimer disease (AD) is characterized by memory deficits and increasingly recognized attentional impairments.
• Specific attention components, like sustained and spatial attention, are notably disrupted in mild AD.
• The basal forebrain cholinergic system (BFCS), including the nucleus basalis of Meynert (nbM), shows significant neuronal loss in AD.

Purpose of the Study:

• To review evidence linking attentional impairments in AD to BFCS damage.
• To explore the potential of cholinergic system stimulation for improving attention in AD.
• To assess the utility of cholinergic drugs in other attentional disorders like Parkinson's disease.

Main Methods:

• Review of human and nonhuman neuropsychopharmacology studies.
• Analysis of the role of BFCS in cortical and subcortical attentional networks.
• Evaluation of cognitive task performance in AD patients treated with cholinergic agents.

Main Results:

• Evidence suggests BFCS damage contributes to attentional deficits in AD.
• Cholinergic stimulation via tacrine and nicotine demonstrated significant improvements in objective cognitive tasks for AD patients.
• Cholinergic drugs may offer therapeutic benefits for attentional dysfunction in Parkinson's disease.

Conclusions:

• Damage to the basal forebrain cholinergic system is implicated in Alzheimer disease-related attentional impairments.
• Cholinergic drug therapy shows promise for enhancing attentional function in AD.
• Further research into cholinergic interventions for attentional disorders is warranted.